Akebia Therapeutics (AKBA) Scheduled to Post Earnings on Thursday

Akebia Therapeutics (NASDAQ:AKBA) will be announcing its earnings results on Thursday, March 7th.

Akebia Therapeutics Stock Performance

Shares of Akebia Therapeutics stock traded down $0.11 on Wednesday, hitting $1.49. The company had a trading volume of 3,939,759 shares, compared to its average volume of 2,264,653. The stock has a market capitalization of $296.32 million, a price-to-earnings ratio of -4.63 and a beta of 0.78. Akebia Therapeutics has a 1 year low of $0.49 and a 1 year high of $1.84. The stock has a 50 day moving average of $1.51 and a 200-day moving average of $1.24.

Wall Street Analyst Weigh In

Several analysts have recently commented on AKBA shares. BTIG Research reissued a “buy” rating and issued a $4.00 price objective on shares of Akebia Therapeutics in a research note on Wednesday, November 29th. HC Wainwright increased their price objective on Akebia Therapeutics from $3.75 to $5.00 and gave the company a “buy” rating in a report on Friday, November 17th.

Insider Transactions at Akebia Therapeutics

In other news, CEO John P. Butler sold 46,570 shares of the firm’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $1.58, for a total value of $73,580.60. Following the completion of the transaction, the chief executive officer now directly owns 2,044,580 shares of the company’s stock, valued at $3,230,436.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, CEO John P. Butler sold 37,733 shares of Akebia Therapeutics stock in a transaction on Tuesday, February 27th. The stock was sold at an average price of $1.52, for a total transaction of $57,354.16. Following the completion of the sale, the chief executive officer now owns 2,091,150 shares of the company’s stock, valued at $3,178,548. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO John P. Butler sold 46,570 shares of the business’s stock in a transaction dated Thursday, February 29th. The shares were sold at an average price of $1.58, for a total value of $73,580.60. Following the transaction, the chief executive officer now owns 2,044,580 shares in the company, valued at approximately $3,230,436.40. The disclosure for this sale can be found here. Insiders sold 187,893 shares of company stock valued at $300,598 over the last three months. Company insiders own 3.84% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. BNP Paribas Arbitrage SA boosted its position in Akebia Therapeutics by 123.7% during the 2nd quarter. BNP Paribas Arbitrage SA now owns 90,540 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 50,066 shares in the last quarter. Mirabella Financial Services LLP purchased a new stake in Akebia Therapeutics during the 1st quarter valued at $40,000. HighTower Advisors LLC raised its stake in Akebia Therapeutics by 18.4% during the 1st quarter. HighTower Advisors LLC now owns 70,350 shares of the biopharmaceutical company’s stock valued at $40,000 after buying an additional 10,925 shares during the last quarter. State of Wyoming purchased a new stake in Akebia Therapeutics during the 2nd quarter valued at $44,000. Finally, JPMorgan Chase & Co. increased its stake in shares of Akebia Therapeutics by 1,916.5% in the 1st quarter. JPMorgan Chase & Co. now owns 81,547 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 77,503 shares in the last quarter. Hedge funds and other institutional investors own 27.04% of the company’s stock.

About Akebia Therapeutics

Akebia Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients.